Efficacy evaluation and survival analysis of etoposide+lobaplatin+anlotinib+sintilimab firstline treatment for extensive-stage small-cell lung cancer
10.3969/j.issn.1671-8348.2024.15.008
- VernacularTitle:依托泊苷+洛铂+安罗替尼+信迪利单抗一线治疗ES-SCLC的疗效评价及生存分析
- Author:
Shuai LIU
1
;
Kai ZHANG
;
Xiaoqing ZHANG
;
Zhenyu LI
;
Wei LUAN
Author Information
1. 内蒙古医科大学研究生学院,呼和浩特 010059
- Keywords:
extensive-stage small cell lung cancer;
anti-angiogenic therapy;
immunotherapy;
first-line treatment;
efficacy
- From:
Chongqing Medicine
2024;53(15):2291-2295
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effectiveness evaluation and survival analysis of immune check-point inhibitors combined with anti-angiogenic therapy and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC).Methods Thirty cases of EC-SCLC treated in department of Oncolo-gy,Inner Mongolia Autonomous Region People's Hospital from June 2020 to June 2021 were selected as the study subjects and treated by etoposide+lobaplatin+anlotinib+sintilimab firstline treatment,the therapeutic effect,improvement of living quality and adverse reactions were evaluated.Results The follow up was until August 2023.The median overall survival (OS) time was 17.3(15.1,19.4)months,the 1 year OS rate was 83.3% (95%CI:64.3%-94.1%).The median progression-free (PFS) time was 8.7(6.4,12.1)months,there was 1 case of complete remission (CR),24 cases of partial remission (PR),3 cases of stable disease (SD) and 2 cases of progress of disease (PD),the objective remission rate (ORR) was 83.3%,the disease con-trol rate (DCR) was 93.3%.Twenty-three cases (76.7%) developed different adverse reactions without more than grade three or above adverse reactions occurrence.Conclusion The etoposide+lobaplatin+anlotinib+si-ntilimab firstline treatment regimen obviously prolong median OS and PFS durations,moreover the adverse reactions are controlled.
